Brief: Creso Pharma Reports FY Loss From Ordinary Activities Attributable A$32.8 Mln

Melodiol Global Health

28/02/2023 08:16

Feb 28 (Reuters) - Creso Pharma Ltd  CPH.AX :
    * FY LOSS FROM ORDINARY ACTIVITIES ATTRIBUTABLE A$32.8
MILLION
VERSUS LOSS A$30.0 MILLION
    * FY REVENUE FROM ORDINARY ACTIVITIES A$8.7 MILLION, UP
39.7%

Source text for Eikon:  ID:nASX8qjf89 
Further company coverage:  CPH.AX 

 ((Reuters.Briefs@thomsonreuters.com;))